In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies, the 3rd Gene Therapy […]

12th Annual World ADC London 29th March - 1st April 2022 London The ADC field is going from strength to strength, further catalysed in 2021 by the approvals of Zynlonta and Tivdak respectively, bringing […]

Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. However, increasing resistance and safety issues limit the success of existing […]

2021 was a game-changing year for the NK cell community. Positive clinical results have forced the field to wake up to the potential of these pioneering approaches. Supporting the field […]